chufangao/CTO huggingface dataset:
Clinical trial NCT04552262: Study to Learn More About the Effect of a New Drug Called BAY2327949 on the Blood Flow Through Kidneys in Adult Participants With Moderate Chronic Kidney Disease
Official title: A Randomized, 2-way Crossover, Placebo-controlled, Double-blind Study to Evaluate Effects of Single Oral Doses of BAY 2327949 on Renal Perfusion in Participants With Moderate Chronic Kidney Disease
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-30
Primary completion date: 2020-12-21
Completion date: 2021-05-05
Plan to share individual participant data: UNDECIDED
IPD sharing description: Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT03044795: Response to PARP Inhibitor Predicted by the RAD51 Assay
Official title: Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker
Acronym: REPAIR
Sponsor: University Medical Center Groningen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study never started
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-30
Primary completion date: 2020-11-30
Completion date: 2020-11-30
Plan to share individual participant data: NO
Clinical trial NCT03329378: Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Official title: A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Data Safety Monitoring Board is in agreement with the study findings so far and the stopping rule has been met, which suspends the study treatment arms in March 2021.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-24
Primary completion date: 2021-03-07
Completion date: 2021-03-07
Plan to share individual participant data: NO
Clinical trial NCT04449029: A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Official title: Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Acronym: B-Clear
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 457.0 (ACTUAL)
Number of arms: 8.0
Start date: 2020-07-27
Primary completion date: 2022-03-18
Completion date: 2022-03-18
Clinical trial NCT04952519: Efficacy of Amantadine Treatment in COVID-19 Patients
Official title: Efficacy of Amantadine Treatment in COVID-19 Patients
Acronym: TITAN
Sponsor: Noblewell (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The annual analysis did not show the efficacy of the investigational medicinal product in this application, therefore the study was not continued.
Enrollment: 193.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-30
Primary completion date: 2022-03-10
Completion date: 2022-03-10
Plan to share individual participant data: NO
Clinical trial NCT04343768: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Official title: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Acronym: COVIFERON
Sponsor: Shahid Beheshti University of Medical Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-04-09
Primary completion date: 2020-04-27
Completion date: 2020-04-27
Plan to share individual participant data: YES
IPD sharing description: One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at sina.irvani@sbmu.ac.ir or sina.irvani@gmail.com and submit a proposal with a valuable research question can have access to data and supporting information.
IPD time frame: One year after the publication of the results in a journal.
IPD access criteria: Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at sina.irvani@sbmu.ac.ir or sina.irvani@gmail.com and submit a proposal with a valuable research question.
Clinical trial NCT02927405: Combination of Preoperative Gabapentin and TAP Blocks in Decreasing Postoperative Pain
Official title: Combination of Preoperative Gabapentin and TAP Blocks in Decreasing Postoperative Pain
Sponsor: State University of New York - Downstate Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Did not get the study to take off, did not recruit any subjects, and then closed the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-04
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Plan to share individual participant data: NO
Clinical trial NCT04637009: A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Official title: A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Sponsor: Astex Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: termination due to portfolio prioritization
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-21
Primary completion date: 2023-02-20
Completion date: 2023-02-20
Plan to share individual participant data: NO
Clinical trial NCT01307605: Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma
Official title: Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.
Sponsor: Swiss Group for Clinical Cancer Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: It was decided by the trial team to stop the collection of follow up data in trial SAKK 35/10.
Enrollment: 154.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-02-09
Primary completion date: 2014-06-20
Completion date: 2023-01-25
Plan to share individual participant data: NO
Clinical trial NCT04132375: Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
Official title: A Double-blind, Placebo-controlled, Adaptive, Phase 2/3 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of INM004 in Pediatric Patients With Shiga Toxin-positive Bloody Diarrhea for Prevention of Hemolytic Uremic Syndrome
Sponsor: Inmunova S.A. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Due to COVID pandemia enrolment was stopped on 20March2020
Enrollment: 11.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-17
Primary completion date: 2022-05-04
Completion date: 2022-07-19
Plan to share individual participant data: NO
Clinical trial NCT01548144: Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Official title: A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: PI request
Enrollment: 178.0 (ACTUAL)
Number of arms: 4.0
Start date: 2012-04-30
Primary completion date: 2021-08-26
Completion date: 2021-08-26
Clinical trial NCT03705273: Comparison of Dexamethasone Oral Preparations to Assess Taste and Acceptance in Children With Asthma and Croup
Official title: Comparison of Dexamethasone Oral Preparations to Assess Palatability and Adverse Effects in Children With Asthma and Croup
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Dr. Arnold assisted in designing and initiating study for a pharmacology PhD candidate. The candidate left the institution and study enrollment was terminated.
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-23
Primary completion date: 2020-10-02
Completion date: 2020-10-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05037188: Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
Official title: A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)
Acronym: COVER
Sponsor: Biocad (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 50.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-08-10
Primary completion date: 2022-04-18
Completion date: 2022-04-18
Plan to share individual participant data: NO
Clinical trial NCT03843710: 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)
Official title: A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis
Acronym: REPAIR-ALS
Sponsor: Clene Nanomedicine (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study execution discontinued at this time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-03-31
Primary completion date: 2022-02-28
Completion date: 2022-03-31
Plan to share individual participant data: NO
Clinical trial NCT03794960: Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
Official title: A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With Established Type 1 Diabetes Mellitus
Acronym: DAY
Sponsor: Tolerion, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Modification to Clinical Development Plan
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-14
Primary completion date: 2021-12-14
Completion date: 2023-12-14
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05286762: Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
Official title: A Phase 3, Double-blind, Randomized, Placebo-controlled, Multi-center, Fixed-dose, Parallel Group Efficacy and Safety in Pediatrics (6-17) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Sponsor: Cingulate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Continuation of the study is not required for NDA submission via the 505(b)(2) pathway
Enrollment: 103.0 (ACTUAL)
Number of arms: 4.0
Start date: 2023-07-25
Primary completion date: 2024-01-24
Completion date: 2024-01-24
Plan to share individual participant data: NO
IPD sharing description: Overall study data as required by FDAAA801 will be shared upon completion of the study.
Clinical trial NCT04005989: Adipose Stromal Cells Injection in the Myocardium for Induction of Revascularization
Official title: Adipose Stromal Cells Injection in the Myocardium for Induction of Revascularization
Acronym: ADMIRE
Sponsor: Hospital do Coracao (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Due to logistic issues during COVID-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-12-01
Primary completion date: 2022-11-30
Completion date: 2022-12-20
Clinical trial NCT05394350: A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Official title: A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business Reasons
Enrollment: 27.0 (ACTUAL)
Number of arms: 6.0
Start date: 2022-07-07
Primary completion date: 2023-09-07
Completion date: 2023-09-07
Limitations and caveats: The decision to close study enrollment was based on review of data from the dose escalation phase and Sponsor prioritization. The decision to stop enrollment was not due to any safety concerns, and there were no safety signals observed during the study.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT04218123: Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Official title: Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes
Sponsor: Medical University of South Carolina (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-05
Primary completion date: 2023-09-13
Completion date: 2023-09-14
Limitations and caveats: This study was designed in 2019 with a power analysis that estimated a 20% placebo response in Meniere's Disease. This was a gross underestimation in hindsight. A systematic review with meta-analysis published in 2023 has illustrated that this effect is much stronger, closer to 50% in patients with Meniere's Disease, which may affect the ability to detect symptomatic differences between venlafaxine and placebo treatment periods, respectively.
Plan to share individual participant data: NO
Clinical trial NCT04418297: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The termination criteria of the protocol was met during dose escalation
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-23
Primary completion date: 2022-11-22
Completion date: 2022-11-22
Clinical trial NCT04965688: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
Official title: Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
Acronym: SPOCK
Sponsor: Inova Health Care Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of enrollment to meet the primary and secondary study goals
Enrollment: 2.0 (ACTUAL)
Start date: 2021-08-08
Primary completion date: 2024-03-13
Completion date: 2024-03-13
Plan to share individual participant data: NO
Clinical trial NCT04719832: Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Official title: A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Acronym: SWIFT-1
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 395.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-17
Primary completion date: 2023-11-21
Completion date: 2023-11-21
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03259165: Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial
Official title: Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial (N-FURIOUS)
Acronym: N-FURIOUS
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: COVID-19 pandemic. Initially had planned to resume study, but ultimately decided to close.
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-14
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Limitations and caveats: Due to the COVID-19 pandemic, enrollment was halted. The nature of the study was to enroll patients with AHF signs and symptoms. The principle symptom is shortness of breath, a common symptom during the peak of COVID-19. Further, employees were not allowed into the ED setting to enroll patients, when much less was known about COVID-19.
Plan to share individual participant data: NO
Clinical trial NCT04963270: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 188.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-19
Primary completion date: 2024-01-29
Completion date: 2024-09-02
Clinical trial NCT03338920: Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
Sponsor: Currax Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: eDiary data collected not sufficient to utilize in the analysis of protocol endpoints
Enrollment: 159.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-02
Primary completion date: 2022-04-11
Completion date: 2022-04-11
Clinical trial NCT04175509: Improving Post-Operative Pain and Recovery in Gynecologic Surgery
Official title: Improving Post-Operative Pain and Recovery in Gynecologic Surgery
Sponsor: Aultman Health Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-23
Primary completion date: 2021-06-01
Completion date: 2021-06-01
Limitations and caveats: Due to the COVID-19 pandemic, many patients were prohibited to stay overnight in the hospital. Therefore, many patients were discharged home before 24 hours after surgery. This is primarily why the primary and secondary outcomes were analyzed at shorter time intervals (6 hours post-op and 12 hours-op) as well.
Clinical trial NCT04979793: Role of L-citrulline in Prevention of Pregnancy Associated Hypertension
Official title: Role of L-citrulline in Prevention of Pregnancy Associated Hypertension in Nulliparous Women
Sponsor: The University of Texas Medical Branch, Galveston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: At the request of the PI
Enrollment: 338.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2021-07-28
Primary completion date: 2024-07-30
Completion date: 2024-07-30
Plan to share individual participant data: NO
Clinical trial NCT04806945: A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
Official title: A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin/Cisplatin and Paclitaxel) vs Chemotherapy (Carboplatin/Cisplatin and Paclitaxel)in Patients With Advanced Cervical Cancer
Sponsor: Shanghai Henlius Biotech (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The sponsor terminated the trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-30
Primary completion date: 2024-02-15
Completion date: 2024-10-30
Plan to share individual participant data: NO
Clinical trial NCT04584307: Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
Official title: Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant (Immuno-POWER Trial): Big Ten Cancer Research Consortium BTCRC-MM19-428
Acronym: Immuno-POWER
Sponsor: Big Ten Cancer Research Consortium (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funder pulled support/funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-04-30
Primary completion date: 2023-12-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03176316: The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus
Official title: The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus
Acronym: FusionIleus
Sponsor: Loyola University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was terminated by the Institutional Review Board.
Enrollment: 53.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-20
Primary completion date: 2020-02-20
Completion date: 2020-02-20
Plan to share individual participant data: NO
IPD sharing description: There are no plans to share individual participant data with other researchers